Detalhe da pesquisa
1.
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
BMC Cancer
; 13: 399, 2013 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24004638
2.
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol
; 248(4): 467-76, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19669678
3.
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Clin Ther
; 30(12): 2436-51, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19167602
4.
Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.
Expert Opin Drug Saf
; 12(4): 455-63, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23510293
5.
Ranibizumab for neovascular age-related macular degeneration.
Am J Health Syst Pharm
; 65(19): 1805-14, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18796421